Sanofi Signs an Agreement with Kymera to Advance Novel Protein Degrader Therapies Worth Up to $2.1B

 Sanofi Signs an Agreement with Kymera to Advance Novel Protein Degrader Therapies Worth Up to $2.1B

Sanofi Signs an Agreement with Kymera to Advance Novel Protein Degrader Therapies Worth Up to $2.1B

Shots:

  • Kymera to receive $150M up front, $2B as development, regulatory and commercial milestones along with royalties on sales of therapies. Additionally, the company has an option to develop and commercialize the two programs in the US while retaining global rights to its IRAK4 program in oncology indications.
  • Sanofi will get a global right to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases and a second undisclosed preclinical program
  • Kymera will advance the IRAK4 program through the P-I study, afterward, Sanofi will be further responsible for its development and will lead all clinical development activities for the second program. IRAK4 is a key protein involved in inflammation mediated by the activation of TLRs and IL-1Rs

Click here ­ to­ read full press release/ article | Ref: PRNewswire | Image: WRVO

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post